The development of a glucose-responsive 'closed-loop' insulin delivery system mimicking pancreatic function has the potential to greatly improve quality of life and health in diabetics. Current systems couple implantable continuous glucose monitors to implantable pumps, which deliver insulin subcutaneously via a cannula. However, issues surrounding multiple calibrations, a 'lag' in blood glucose measurement and risk of infection have hampered their use in clinical practice.
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Yu et al. describe a glucose-responsive-microneedle patch that can be painlessly applied to the skin and that releases insulin in response to glucose. The nanoparticles in each needle contain insulin and glucose oxidase. These molecules are surrounded by hypoxia-sensitive hyaluronic acid-based vesicles which rapidly dissociate and release encapsulated insulin under the local hypoxic environment, caused by the enzymatic oxidation of glucose in the hyperglycemic state.
Using mouse models of type 1 diabetes, the authors demonstrate that the patch effectively regulates glucose after dosing with a glucose load. Once blood glucose normalized, insulin release ceased. Serial administration of patches produced prolonged euglycaemia. The faster responsiveness of this approach holds promise in helping people with diabetes manage their condition more safely and effectively. Suspected acute myocardial infarction (MI) still presents a significant diagnostic problem in the emergency department. Delays in diagnosis can increase morbidity and mortality or lead to unnecessary further investigation. Cardiac troponin (cTn) measurement has enabled more effective triage of patients, and recent highsensitivity cTn (hs-cTn) assays allow measurement of very low levels if cTn with greater precision.
This study investigated the use of hs-cTnI at presentation and 1 h to produce an algorithm that could triage patients into MI 'rule-in', 'rule-out', or 'observe' groups. Of 1811 patients included, half were randomly selected as a derivation cohort in which the algorithm was developed, and the remaining half were assigned as a validation cohort. The algorithm was based on baseline and absolute change of hs-cTnI at 1 h.
The algorithm in the validation cohort classified 50.5% of patients as 'rule-out ', 19% as 'rule-in' and 30.5% as 'observe', allowing more rapid triage than that by current guidance. The authors suggest that the negative and positive predictive values determined are higher than the current algorithms in clinical use. The use of such hs-cTnI algorithms in other clinical settings requires investigation, and validation of other hs-cTnI assays is necessary. However, this study indicates that earlier diagnosis of suspected MI is indeed feasible. 
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